Saturday 17 October 2026
Export SMMT’s income statement to Excel — free account
Summit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00. In the quarter to June 2026, EPS grew 63.2% and free cash flow fell 112.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.63
0.74
−4.81%
Follow SMMT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(292.49%) | (206.10%) | (270.95%) | (192.50%) | |
| (241.08%) | (181.94%) | (233.81%) | (159.09%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(505.42%) | (166.51%) | (225.44%) | (138.35%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.36) | (0.43) | (0.50) | (0.59) | |
Free Cash Flow |
(270.17) | (323.59) | (384.53) | (459.82) | |
Capital Expenditures |
(0.51) | (0.66) | (0.48) | (1.39) | |
| Other line items | |||||
Cash ROIC |
(62.66%) | (23.57%) | (33.58%) | (34.81%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.29 | 0.30 | 0.32 | 0.54 | |
Depreciation/Fixed assets |
0.16 | 0.14 | 0.10 | 0.10 | |
Capex/Depreciation |
(4.02) | (4.50) | (2.91) | (7.98) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.36) | (0.43) | (0.50) | (0.59) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates